Novartis

Novartis Expands Partnership with Medicines for Malaria Venture to Develop Next-Generation Antimalarial Treatment

Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
Summary: 

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment 

  • Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation

  • KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle

  • Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies

Press Release

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment 

  • Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation

  • KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle

  • Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies

BeatRHD! Experts from Across the World Meet in Mexico to Talk About Heart Diseases

Article

From June 4-7 Novartis scientists participate in the World Congress of Cardiology & Cardiovascular Health (WCC) in Mexico. This Congress brings together thousands of heart health professionals from around the world. One of the key topics is rheumatic heart disease (RHD).

Africa Has a New Health Challenge, and We Need a Plan to Fight It

Blog written by Harald Nusser, Global Head Novartis Access
Blog

While the headlines might focus on Ebola or yellow fever, Africa is slowly winning the fight against infectious diseases. They will remain a challenge for decades to come, but the real threat of the future is expected to come from elsewhere: non-communicable diseases (NCDs) like diabetes, cardiovascular disease and cancer.

Novartis Foundation and Partners Launch Innovative Hypertension Program in Vietnam

Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Summary: 
  • Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation 

  • Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers

  • Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control

  • Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact 

Press Release
  • Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation 

  • Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers

  • Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control

  • Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact 

More than 750 Million Anti Malaria Treatments for Adults and Children Provided Without Profit

Malaria is still one of the most deadly diseases in developing countries
Article

Today is World Malaria Day. Malaria is preventable and curable, yet it is still one of the most deadly diseases in developing countries. Despite extraordinary progress in the fight against malaria over the last 15 years, the disease still claims the life of a child every two minutes.

Experts Discuss Better Treatments Against Parasitic Diseases

The Novartis Institute for Tropical Diseases convenes parasitology experts in Zambia
Article

On April 4-8 2016, the Novartis Institute for Tropical Diseases (NITD) held a Symposium on Parasitology in Lusaka, Zambia, bringing together international and local experts in the field with the aim of engaging in productive scientific exchange on parasitic diseases - including malaria, sleeping sickness (Human African Trypanosomiasis), Chagas, leishmaniasis, and cryptosporidiosis.

Novartis and Red Cross Partner to Tackle Chronic Diseases in Refugee Populations

Novartis will provide medicines for high blood pressure and diabetes
Article

Syrian refugees in Lebanon suffering from chronic diseases face difficulties accessing diagnosis, medicines and ongoing care. The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up for refugees, as well as members of their Lebanese host families, who suffer from chronic diseases. 

First Novartis Access Treatments Delivered to Kenya

Shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer
Article

We are pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer. The medicines are currently stored in the MEDS warehouse (Mission for Essential Drugs and Supplies) in Nairobi. MEDS is a faith-based not-for-profit medical supply chain and capacity building organization in Kenya.

Novartis Foundation Commemorates World Leprosy Day with its Continued Efforts to go the Last Mile Toward Elimination

2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease
Summary: 
  • 2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease

  • New strategy from the Novartis Foundation to accelerate elimination is focused on interrupting transmission of the disease

  • Last year Novartis renewed its commitment with the WHO to donate multidrug therapy to treat leprosy through the year 2020

  • More than 200,000 people are diagnosed with leprosy every year; approximately 10% of those are children, indicating continued spread of the disease
Press Release
  • 2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease

  • New strategy from the Novartis Foundation to accelerate elimination is focused on interrupting transmission of the disease

  • Last year Novartis renewed its commitment with the WHO to donate multidrug therapy to treat leprosy through the year 2020

  • More than 200,000 people are diagnosed with leprosy every year; approximately 10% of those are children, indicating continued spread of the disease

Novartis Releases 2015 Corporate Responsibility Performance Report

Article

Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.

Pages

Subscribe to Novartis